Threshold slashes staff in effort to cut burn rate

Refocusing its R&D efforts, Threshold Pharmaceuticals is cutting its 44-person workforce down to 32--including two senior executives. Threshold plans to concentrate on its hypoxia-activated prodrug program and the ongoing clinical trials of glufosfamide. Cathleen Davis, vice president of finance and controller, and Kevin Kaster, senior vice president, corporate development, are both on the way out.

In an effort to further reduce its burn rate, Threshold announced plans to reduce consulting and other "external" expenses. A little more than two weeks ago, Threshold announced that it would halt enrollment in a Phase II trial of glufosfamide after recording disappointing data in the study. Threshold says it has enough cash to fund operations through the first quarter of 2009.

 

- check out the release for more info

Related Articles:
Threshold halts lung cancer study. Report
Threshold delays release of glufosfamide analysis. Report
Threshold slashes staff in wake of quarterly loss. Report
Threshold shares drop after Phase III suspension. Report

Suggested Articles

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.

Argenx’s phase 3 data set the bar for rival FcRn assets in development at Alexion, Immunovant and UCB.

Tufts scientists discovered that two anti-seizure drugs can lessen the development of brain defects caused by nicotine exposure in frogs.